{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:45:52Z","timestamp":1792633552724,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.jgar.2019.06.013","type":"journal-article","created":{"date-parts":[[2019,6,18]],"date-time":"2019-06-18T11:29:31Z","timestamp":1560857371000},"page":"348-353","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["In vitro interaction profiles of the new antitubercular drugs bedaquiline and delamanid with moxifloxacin against clinical Mycobacterium tuberculosis isolates"],"prefix":"10.1016","volume":"19","author":[{"given":"Yuvaraj","family":"Chandramohan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkatesan","family":"Padmanaban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramalingam","family":"Bethunaickan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srikanth","family":"Tripathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumya","family":"Swaminathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uma Devi","family":"Ranganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2019.06.013_bib0005","series-title":"Global tuberculosis report 2017","author":"World Health Organization (WHO)","year":"2017"},{"key":"10.1016\/j.jgar.2019.06.013_bib0010","first-page":"1","article-title":"Treatment of tuberculosis","volume":"52","author":"American Thoracic Society, CDC, Infectious Diseases Society of America","year":"2003","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jgar.2019.06.013_bib0015","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1378\/chest.111.5.1168","article-title":"Noncompliance with directly observed therapy for tuberculosis. Epidemiology and effect on the outcome of treatment","volume":"111","author":"Burman","year":"1997","journal-title":"Chest"},{"key":"10.1016\/j.jgar.2019.06.013_bib0020","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.mib.2011.07.022","article-title":"New tuberculosis drugs on the horizon","volume":"14","author":"Cole","year":"2011","journal-title":"Curr Opin Microbiol"},{"key":"10.1016\/j.jgar.2019.06.013_bib0025","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2217\/fmb.11.46","article-title":"Tuberculosis drugs: new candidates and how to find more","volume":"6","author":"Sala","year":"2011","journal-title":"Future Microbiol"},{"key":"10.1016\/j.jgar.2019.06.013_bib0030","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.4155\/fmc.11.82","article-title":"The TB Alliance: overcoming challenges to chart the future course of TB drug development","volume":"3","author":"Ginsberg","year":"2011","journal-title":"Future Med Chem"},{"key":"10.1016\/j.jgar.2019.06.013_bib0035","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1126\/science.1106753","article-title":"A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis","volume":"307","author":"Andries","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.jgar.2019.06.013_bib0040","doi-asserted-by":"crossref","first-page":"15629","DOI":"10.1073\/pnas.0507850102","article-title":"Changes in energy metabolism of Mycobacterium tuberculosis in mouse lung and under in vitro conditions affecting aerobic respiration","volume":"102","author":"Shi","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jgar.2019.06.013_bib0045","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1093\/cid\/cix992","article-title":"Bedaquiline resistance: its emergence, mechanism, and prevention","volume":"66","author":"Nguyen","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2019.06.013_bib0050","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1128\/AAC.00037-14","article-title":"Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis","volume":"58","author":"Hartkoorn","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2019.06.013_bib0055","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1038\/ncomms4369","article-title":"Delayed bactericidal response of Mycobacterium tuberculosis to bedaquiline involves remodelling of bacterial metabolism","volume":"5","author":"Koul","year":"2004","journal-title":"Nat Commun"},{"key":"10.1016\/j.jgar.2019.06.013_bib0060","doi-asserted-by":"crossref","first-page":"e466","DOI":"10.1371\/journal.pmed.0030466","article-title":"OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice","volume":"3","author":"Matsumoto","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.jgar.2019.06.013_bib0065","series-title":"Deltyba (delamanid). Summary of opinion (initial authorisation)","author":"European Medicines Agency (EMA)","year":"2013"},{"key":"10.1016\/j.jgar.2019.06.013_bib0070","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1126\/science.1164571","article-title":"PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release","volume":"322","author":"Singh","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.jgar.2019.06.013_bib0075","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1183\/09031936.00176314","article-title":"Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid","volume":"45","author":"Wells","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jgar.2019.06.013_bib0080","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1128\/AAC.01476-12","article-title":"In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis","volume":"56","author":"Lechartier","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2019.06.013_bib0085","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ijantimicag.2016.10.020","article-title":"Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir\/ritonavir or nevirapine in patients with HIV and drug-resistant tuberculosis","volume":"49","author":"Brill","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2019.06.013_bib0090","doi-asserted-by":"crossref","first-page":"5976","DOI":"10.1128\/AAC.00509-16","article-title":"Delamanid coadministered with antiretroviral drugs or antituberculosis drugs shows no clinically relevant drug\u2013drug interactions in healthy subjects","volume":"60","author":"Mallikaarjun","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2019.06.013_bib0095","series-title":"Guidelines for the programmatic management of drug-resistant tuberculosis","author":"World Health Organization (WHO)","year":"2011"},{"key":"10.1016\/j.jgar.2019.06.013_bib0100","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1128\/AAC.46.8.2720-2722.2002","article-title":"Resazurin microtiter assay plate: simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis","volume":"46","author":"Palomino","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2019.06.013_bib0105","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1128\/JCM.00244-07","article-title":"Drug susceptibility testing of Mycobacterium tuberculosis complex by use of a high-throughput, reproducible, absolute concentration method","volume":"45","author":"Van Klingeren","year":"2007","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2019.06.013_bib0110","first-page":"412","article-title":"Laboratory diagnosis of histoplasmosis and tuberculosis [in Chinese]","volume":"29","author":"Chen","year":"2006","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"key":"10.1016\/j.jgar.2019.06.013_bib0115","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1164\/ajrccm\/143.2.268","article-title":"Comparison of bacteriostatic and bactericidal activity of isoniazid and ethionamide against Mycobacterium avium and Mycobacterium tuberculosis","volume":"143","author":"Heifets","year":"1991","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.jgar.2019.06.013_bib0120","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1128\/AAC.01601-09","article-title":"In vitro interactions between new antitubercular drug candidates SQ109 and TMC207","volume":"54","author":"Reddy","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2019.06.013_bib0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/dkg301","article-title":"Synergy, antagonism, and what the chequerboard puts between them","volume":"52","author":"Odds","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2019.06.013_bib0130","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1128\/AAC.36.3.548","article-title":"Antagonism between isoniazid and the combination pyrazinamide\u2013rifampin against tuberculosis infection in mice","volume":"36","author":"Grosset","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2019.06.013_bib0135","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00913-17","article-title":"Bactericidal and sterilizing activity of a novel regimen with bedaquiline, pretomanid, moxifloxacin, and pyrazinamide in a murine model of tuberculosis","volume":"61","author":"Li","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2019.06.013_bib0140","series-title":"WHO treatment guidelines for drug-resistant tuberculosis: 2016 update. WHO\/HTM\/TB\/201604","author":"World Health Organization (WHO)","year":"2016"},{"key":"10.1016\/j.jgar.2019.06.013_bib0145","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1038\/emi.2014.21","article-title":"Association of gyrA\/B mutations and resistance levels to fluoroquinolones in clinical isolates of Mycobacterium tuberculosis","volume":"3","author":"Li","year":"2014","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.jgar.2019.06.013_bib0150","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/emmm.201303575","article-title":"Towards a new combination therapy for tuberculosis with next generation benzothiazinones","volume":"6","author":"Makarov","year":"2014","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.jgar.2019.06.013_bib0155","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1128\/AAC.05708-11","article-title":"SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis","volume":"56","author":"Tahlan","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2019.06.013_bib0160","doi-asserted-by":"crossref","first-page":"222","DOI":"10.4103\/0976-500X.136121","article-title":"Delamanid: a new armor in combating drug-resistant tuberculosis","volume":"5","author":"Xavier","year":"2014","journal-title":"J Pharmacol Pharmacother"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716519301572?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716519301572?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:53:27Z","timestamp":1761990807000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716519301572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":32,"alternative-id":["S2213716519301572"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2019.06.013","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro interaction profiles of the new antitubercular drugs bedaquiline and delamanid with moxifloxacin against clinical Mycobacterium tuberculosis isolates","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2019.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 International Society for Antimicrobial Chemotherapy. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}